Humana Inc. vs Johnson & Johnson: Strategic Comparison

This in-depth comparison examines Humana Inc. and Johnson & Johnson across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Humana Inc. on its own, evaluating Johnson & Johnson, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Humana Inc. and Johnson & Johnson is widest.

On the headline numbers, Humana Inc. reports annual revenue of $129.7B against $94.2B for Johnson & Johnson, while their respective market capitalizations stand at $48.2B and $643.9B. Both Humana Inc. and Johnson & Johnson are headquartered in United States, so they compete in a shared home market and regulatory environment.

Humana Inc.: Humana Inc. is a Fortune 50 health company headquartered in Louisville, Kentucky. It serves roughly 7.2 million individual and group Medicare Advantage members, millions of stand-alone Part D, Medicaid, and TRICARE beneficiaries, and patients of its CenterWell clinics, pharmacy, and home health services. Unlike diversified rivals, Humana gets nearly all of its medical membership from government-funded programs, so it is effectively a bet on Medicare Advantage and senior care.

Johnson & Johnson: Johnson & Johnson is one of the largest healthcare companies in the world by revenue and market value. Once known for Band-Aid, Tylenol, and baby powder, it moved those consumer brands into Kenvue in 2023 and now reports two segments: Innovative Medicine and MedTech. In 2025 it generated $94.2 billion in sales with about 140,800 employees, and in 2026 it is aiming for more than $100 billion in revenue during its 140th year.

Humana Inc. and Johnson & Johnson pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Humana Inc. and Johnson & Johnson.

Humana Inc. business model: Humana runs two reporting segments. The Insurance segment sells individual and group Medicare Advantage plans, stand-alone Medicare Part D drug plans, state Medicaid contracts, and administers TRICARE for the Defense Health Agency. It is paid largely by the federal government on a per-member, per-month basis adjusted for each member's health risk, and keeps the difference between those premiums and medical and pharmacy claims plus operating costs. The CenterWell segment provides services: CenterWell Senior Primary Care clinics, CenterWell Pharmacy (mail-order and specialty), and CenterWell Home Health. CenterWell serves Humana members and members of other plans, and it gives Humana direct influence over care costs for its own seniors.

Johnson & Johnson business model: J&J makes money in two ways. Innovative Medicine (about 64% of FY2025 sales, $60.4 billion) sells patented prescription medicines to wholesalers, specialty pharmacies, hospitals, and governments; key products include DARZALEX for multiple myeloma, TREMFYA and STELARA in immunology, ERLEADA in prostate cancer, CARVYKTI cell therapy, and CAPLYTA, added through the 2025 Intra-Cellular Therapies deal. Margins depend on patent protection, so growth relies on launching new drugs as older ones such as STELARA face biosimilars. MedTech (about 36%, $33.8 billion) sells surgical tools, wound closure, orthopaedic implants, electrophysiology catheters and mapping systems, Abiomed heart pumps, Shockwave lithotripsy devices, and contact lenses to hospitals and surgery centers, with much of the revenue coming from recurring disposables and implants.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Humana Inc. stack up against those of Johnson & Johnson.

Humana Inc. competitive advantage: Humana's edge is depth in one market. It is the second-largest Medicare Advantage insurer after UnitedHealth, it has decades of experience pricing senior risk, and it owns care-delivery assets built for seniors: CenterWell Senior Primary Care clinics, a large mail-order pharmacy, and CenterWell Home Health. Owning those services lets Humana manage chronic conditions and pharmacy spending directly instead of only paying claims. The tradeoff is concentration: unlike UnitedHealth, CVS/Aetna, or Elevance, it has no large commercial or PBM business to offset a bad Medicare year.

Johnson & Johnson competitive advantage: J&J's edge is breadth plus balance-sheet strength. It runs one of the largest pharmaceutical R&D budgets in the industry, holds a AAA credit rating from S&P (one of only two US companies with that rating, alongside Microsoft), and sells into hospitals across pharmaceuticals and devices at the same time. That diversification lets it absorb clinical-trial failures and patent expirations that would sink a single-product biotech, and fund multibillion-dollar acquisitions such as Abiomed, Shockwave Medical, and Intra-Cellular Therapies with cash and investment-grade debt.

Future prospects matter as much as current results. The growth strategies below explain how Humana Inc. and Johnson & Johnson each plan to expand from here.

Humana Inc. growth strategy: Humana's strategy under Jim Rechtin is to grow Medicare Advantage membership while rebuilding margins and quality scores. Key moves include completing the exit from employer-group commercial medical coverage in 2025, adding more than 1 million MA members for 2026, pruning about 600,000 members' worth of underperforming plans for 2027, investing in Star Ratings operations, and expanding CenterWell Senior Primary Care and CenterWell Pharmacy so that more member care runs through Humana-owned services. It is also bidding for and growing state Medicaid contracts, with a focus on members eligible for both Medicare and Medicaid.

Johnson & Johnson growth strategy: J&J is narrowing its portfolio toward higher-growth areas. It spun off consumer health as Kenvue in 2023, announced in October 2025 that it will separate its orthopaedics business as DePuy Synthes, and used acquisitions to refill its pipeline: Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025). Internally it is expanding TREMFYA and CAPLYTA labels, advancing multiple myeloma combinations such as TALVEY plus DARZALEX FASPRO, and developing the OTTAVA soft-tissue surgical robot to compete with Intuitive Surgical's da Vinci.

A closer look at the financial trajectory of Humana Inc. and Johnson & Johnson rounds out the comparison.

Humana Inc.: Humana's revenue grew from $54.4 billion in 2016 to $129.66 billion in 2025, driven by Medicare Advantage enrollment and higher per-member payments. Profit moved the other way: net income fell from $3.37 billion in 2020 to $1.21 billion in 2024 and $1.19 billion in 2025 as medical costs rose faster than payments. In 2026 revenue is growing fast again: Q2 2026 revenue was $40.89 billion, up 26.2% year over year, with GAAP EPS of $5.73 and adjusted EPS of $7.61. Year-to-date operating cash flow reached $3.22 billion. Full-year 2026 guidance is adjusted EPS of at least $9.00 and GAAP EPS of at least $6.52, reflecting the Star Ratings bonus headwind.

Johnson & Johnson: J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026.